Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#3953 Olaparib use in a patient diagnosed with BRCA2 mutated adrenocortical carcinoma: A case report

Introduction: Adrenocortical carcinoma (ACC) is a highly lethal endocrine malignancy with an estimated annual incidence of 1.5–2 cases per million. Only a small percentage of ACC cases are associated with hereditary cancer syndromes while, equally only a few cases, have been reported with BRCA mutation. Targeted therapy of ACC with germline mutations is an area of research which renders the treatment approach challenging.

Conference:

Presenting Author:

Authors: Kontana E, Tikas I, Boudina M, Chrysoulidou A, Andreadou A,

Keywords: adrenocortical carcinoma, brca2 mutation, olaparib,

#3813 First report of the phase I LuPARP trial assessing 177Lu-DOTATATE in combination with the PARP inhibitor olaparib in patients with somatostatin positive tumors

Introduction: Patients with metastatic somatostatin receptor positive tumors can be treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. However, all patients do not respond sufficiently, and further treatment optimization is highly warranted. We hypothesize that the tumoricidal effect could be increased by adding a PARP inhibitor which will decrease the ability of the tumor cells to repair DNA-damage, making them more sensitive to radiation and increase the probability of tumor cell death.

Conference:

Presenting Author: Hallqvist A

Authors: Hallqvist A, Sjögren M, Krantz T, Holgersson K, Svensson J,

Keywords: PRRT, 177Lu-DOTATATE, olaparib,